Results 21 to 30 of about 16,037 (203)

Assessment of Quality of Life and Coexistent Allergic Conjunctivitis in Patients with Allergic Rhinitis in Van Province

Turkish Archives of Otorhinolaryngology, 2014
Objective:In this study, we aimed to evaluate coexistent allergic conjunctivitis with allergic rhinitis in Van province and the patients’ quality of life in this region.Methods:A total of 94 patients who were admitted to the Otorhinolaryngology Clinics ...
Ayfer Ulçay Belgü, Yusuf Orhan Uçal, Asiye Ekinci, Meryem Güler Alış, Ömürsen Yıldırım, Denizhan Dizdarorhanucal@gmail.com   +5 more
doaj   +1 more source

Expression of TSLP and Downstream Molecules IL-4, IL-5, and IL-13 on the Eye Surface of Patients with Various Types of Allergic Conjunctivitis

Journal of Ophthalmology, 2016
Background. The pathogenesis of allergic conjunctivitis has not been clearly established. Moreover, previous studies fail to consider human models of allergic conjunctivitis.
Xiaofen Zheng, Juan Yao, Bing Li
doaj   +1 more source

Observer-masked trial comparing efficacy of topical olopatadine (0.1%), bepotastine (1.5%), and alcaftadine (0.25%) in mild to moderate allergic conjunctivitis

Indian Journal of Ophthalmology, 2019
Purpose: With increasing environmental pollution, the incidence of allergic conjunctivitis is increasing. Newer anti-allergic medications with combined anti-histaminic and mast cell stabilization action can help reducing the use of topical steroids for ...
Lakshey Dudeja, Anuja Janakiraman, Ishani Dudeja, Kaustubh Sane, Manohar Babu   +4 more
doaj   +1 more source

IMMUNOPATHOLOGY OF ALLERGIC CONJUNCTIVITIS

European Medical Journal, 2020
Allergic conjunctivitis is predominantly an immunoglobulin E-mediated hypersensitivity reaction to environmental allergens. Allergic diseases affect >30% of the world’s population, of which 40% report associated ocular manifestations.
DeGaulle I. Chigbu, Bhawanjot K. Minhas
doaj  

Skin reactivity in allergic conjunctivitis

Revista Alergia México, 2018
Background: Allergic conjunctivitis is caused by an IgE-mediated mechanism or immediate hypersensitivity due to allergen direct contact on the conjunctival surface of sensitized patients, which elicits mastocyte activation and inflammatory mediators ...
Pablo Andrés Miranda-Machado, Bautista De la Cruz-Hoyos Sánchez   +1 more
doaj   +1 more source

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS‐DAI)

Arthritis Care &Research, Accepted Article.
Objective VEXAS syndrome is characterized by a complex spectrum of inflammatory and hematologic manifestations. Clinical research to identify effective therapies is urgently needed but is hindered by the lack of validated outcome measures. A VEXAS‐specific disease activity index (DAI) is an essential tool for reliably capturing changes in disease ...
Kevin Byram, Heřman Mann, Danielle Hammond, Onima Chowdhury, Sinisa Savic, Yohei Kirino, Carmelo Gurnari, Maël Heiblig, Thibault Comont, Arsène Mekinian, Mrinal M. Patnaik, Lachelle D. Weeks, Gary Ho, Adam Al‐Hakim, Scott Goldberg, Marcela A. Ferrada, Sophie Georgin‐Lavialle, Peter C. Grayson, Emma M. Groarke, Bhavisha Patel, Megan Sullivan, Sarah A. Buckley, Bryan G. Harder, Raman Garcha, David B. Beck, Matthew J. Koster   +25 more
wiley   +1 more source

Effective Performance of the 2022 American College of Rheumatology/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in Pediatric Patients: An ARChiVe Study

Arthritis &Rheumatology, EarlyView.
Objective To assess the 2022 American College of Rheumatology (ACR)/EULAR classification criteria for antineutrophil cytoplasmic antibody–associated vasculitis (AAV) in children with chronic small‐to‐medium vessel vasculitis. Methods A cohort of 574 patients, identified by physician's diagnosis (MD‐diagnosis) in A Registry of Childhood Vasculitis, was ...
David A. Cabral, Else S. Bosman, Nick McPhate, Simranpreet K. Mann, Kirandeep K. Toor, Kimberly A. Morishita, Raashid Luqmani, Michael W. Beresford, James Bistolarides, Sarah Campillo, Sirirat Charuvanij, Kathryn Cook, Paul Dancey, Marietta de Guzman, Samundeeswari Deepak, Barbara Eberhard, Melissa Elder, Samuel Gagne, Katie Harrison, Adam Huber, Archana Khan, Susan Kim, Marisa S. Klein‐Gitelman, Tzielan C. Lee, Suzanne C. Li, Neil Martin, Flora McErlane, L. Nandini Moorthy, Alvaro H. Orjuela, Jonathan Park, Phil Riley, Alan M. Rosenberg, Susan Shenoi, Vidya Sivaraman, Sodality Sutnga, Tamara Tanner, Stacey E. Tarvin, Marinka Twilt, Linda Wagner‐Weiner, Rae S. M. Yeung, Kelly L. Brown, for the ARChiVe Investigators Network within the PedVas Initiative   +41 more
wiley   +1 more source

Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review

Head &Neck, EarlyView.
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell, E. C. Ward, L. R. Wishart, R. Perera, C. Barrett, K. A. Edmiston, E. Mitchell, A. Pigott, R. Pitt, K. Russell, B. A. Chan, R. Ladwa   +11 more
wiley   +1 more source

Prevalence and comorbidity of allergic diseases in preschool children [PDF]

Korean Journal of Pediatrics, 2013
PurposeAllergic disease and its comorbidities significantly influence the quality of life. Although the comorbidities of allergic diseases are well described in adult populations, little is known about them in preschool children. In the present study, we
Hyeong Yun Kim, Eun Byul Kwon, Ji Hyeon Baek, Youn Ho Shin, Hye Yung Yum, Hye Mi Jee, Jung Won Yoon, Man Yong Han   +7 more
doaj   +1 more source

Bilateral Ophthalmoplegia After Neoadjuvant Pembrolizumab for Oral Cavity Squamous Cell Carcinoma

The Laryngoscope, EarlyView.
The role of immune checkpoint inhibition (ICI) therapy in the treatment of head and neck squamous cell carcinoma (HNSCC) is expanding with increased utilization of neoadjuvant and adjuvant pembrolizumab in the setting of locally advanced disease. This report describes the presentation and management of the first known case of pembrolizumab‐induced ...
Leonard E. Estephan, Peter Jacoby, David M. Cognetti, Steven A. Manobianco   +3 more
wiley   +1 more source